{'fraction_non_alphanumeric': 0.027722772277227723, 'fraction_numerical': 0.01287128712871287, 'mean_word_length': 5.39873417721519, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Mammary Analogue Secretory Carcinoma of the Parotid Gland in a Pediatric Patient

S alivary neoplasms comprise 1% to 3% of all head and neck malignancies. Less than 5% of salivary gland malignancies are diagnosed in children. A recent study in adult patients describes a new salivary gland tumor, mammary analogue secretory carcinoma of the salivary gland (MASC). This lesion has pathological characteristics similar to secretory carcinoma of the breast, salivary acinic cell carcinoma, and low-grade cystadenocarcinoma. MASC is frequently associated with a translocation, t(12;15)(p13;q25), resulting in the fusion gene ETV6-NTRK3. This translocation has been demonstrated consistently in secretory carcinoma of the breast. The tyrosine kinase encoded by this fusion gene has been directly related to transformation of epithelial cells in mouse mammary glands. Children’s Memorial Hospital institutional review board approval was obtained, and we report the first case of MASC in the parotid gland of a child.